Analysis-China biotech licensing boom to hit record in 2026 as pipeline swells

By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry analysts predicting licensing deals will surge to a fresh record this year. The value of such deals signed by ‌companies in the greater China region - which includes Hong Kong, Macau and Taiwan - rose nearly tenfold last year from 2021 to an unprecedented $137.7 billion, according ‌to data ...